NasdaqGS:IBRXBiotechs
Assessing ImmunityBio (IBRX) Valuation After New ANKTIVA Lung Cancer Efficacy Data
ImmunityBio’s ANKTIVA lung cancer data and what it means for investors
ImmunityBio (IBRX) reported statistically significant immune restoration and a link between lymphocyte recovery and survival in non small cell lung cancer from its ANKTIVA clinical program, based on the QUILT-2.023 and QUILT-3.055 studies.
The company highlighted results across 151 checkpoint experienced patients who had progressed after standard treatments, describing these data as foundational safety and efficacy...